Cover Image
市場調查報告書

全球腎細胞癌症治療藥市場預測

Global Renal Cell Carcinoma Drugs Market 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 352582
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
全球腎細胞癌症治療藥市場預測 Global Renal Cell Carcinoma Drugs Market 2020
出版日期: 2016年02月01日 內容資訊: 英文 65 Pages
簡介

全球腎細胞癌症 (RCC) 治療藥市場,預計至2020年達到40億美元。

本報告提供全球腎細胞癌症治療藥市場相關調查分析,市場現況與展望,主要醫藥品的資訊與收益,臨床開發狀況,主要推動因素與課題,最新的趨勢與發展,策略性聯盟等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 腎細胞癌症:簡介

第4章 推動因素與課題

  • 推動因素
  • 課題

第5章 腎細胞癌症治療藥市場概要

第6章 主要醫藥品

  • Sutent
  • Votrient
  • Afinitor
  • Nexavar
  • Inlyta
  • Avastin
  • Proleukin
  • Torisel
  • Opdivo

第7章 市場區隔:各地區

  • 北美
  • 歐洲
  • 亞太地區

第8章 腎細胞癌症治療藥開發平台

第9章 趨勢與發展

第10章 M&A

第11章 競爭情形

第12章 主要企業分析

  • Pfizer Inc.
  • F.Hoffmann-La Roche AG
  • Novartis
  • GlaxoSmithKline
  • Bayer AG
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • AstraZeneca
  • Eli Lilly & Co.
  • Amgen Inc.

圖表

目錄

Renal cell carcinoma, also called renal adenocarcinoma, is a disease in which malignant or cancerous cells are found in the lining of tubules in the kidney. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. Various tests, like ultrasound, urine analysis, intravenous pyelogram, CT scan, MRI and biopsy, are available now-a-days that can help in early diagnosis of this disease. The drugs which are used for the treatment of the renal cell carcinoma include the likes of Sutent, Votrient, Inlyta and Nexavar among others. The latest addition to this lot is Opdivo by Bristol-Myers Squibb. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.

According to the report “Global Renal Cell Carcinoma Drugs Market 2020”, the renal cell carcinoma drugs market is anticipated to cross US$ 4 Billion by 2020. The report provides a detailed analysis of the market for these drugs. The report provides the current and forecasted market for renal cell carcinoma drugs.

Moreover, the report provides information and revenues of the major branded drugs in the market for this disease. The segmentation of renal cell carcinoma drugs market has been done in the report on the basis of different geographical regions. North America is accounted for the largest share of the renal cell carcinoma market. This high share was attributed to colossal patient pool, large number of commercially available drugs for the treatment of renal cell carcinoma, favourable healthcare insurance coverage, and impressive healthcare systems customized for the pharmaceutical sector. However, the Asia Pacific market is poised to witness the highest growth in coming years owing to improving healthcare facilities in the region coupled with rising patient pool.

It also highlights RCC drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth.

The later part of the report discusses some of the prominent players in the global renal cell carcinoma drug market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Renal Cell Carcinoma - An Introduction

4. Drivers and Challenges

  • 4.1. Drivers
    • 4.1.1. Increasing Geriatric Population
    • 4.1.2. Quick Diagnosis with Modern Imaging Techniques
    • 4.1.3. Increasing Risk from Lifestyle Related Factors
    • 4.1.4. Grants and Tax Credits
  • 4.2. Challenges
    • 4.2.1. High Cost
    • 4.2.2. Lack of Disease History Awareness & Research Participants
    • 4.2.3. Rising Patent Cliff

5. Renal Cell Carcinoma Drugs Market Overview

6. Major Branded Drugs

  • 6.1. Sutent
  • 6.2. Votrient
  • 6.3. Afinitor
  • 6.4. Nexavar
  • 6.5. Inlyta
  • 6.6. Avastin
  • 6.7. Proleukin
  • 6.8. Torisel
  • 6.9. Opdivo

7. Market Segmentation By Geography

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific

8. Renal Cell Carcinoma Drugs Pipeline

9. Trends and Developments

  • 9.1. Positive Outcomes from Clinical Trials Driving RCC Market
  • 9.2. ADCs - A Novel Treatment Option for RCC

10. Mergers and Acquisitions

11. Competitive Landscape

12. Key Players Analysis

  • 12.1. Pfizer Inc.
  • 12.2. F.Hoffmann-La Roche AG
  • 12.3. Novartis
  • 12.4. GlaxoSmithKline
  • 12.5. Bayer AG
  • 12.6. Bristol-Myers Squibb
  • 12.7. Merck & Co., Inc.
  • 12.8. AstraZeneca
  • 12.9. Eli Lilly & Co.
  • 12.10. Amgen Inc.

List of Figures:

  • Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
  • Figure 5-1: Global - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
  • Figure 6-1: Sutent - Global Revenue (Billion US$), 2011-2014
  • Figure 6-2: Votrient - Global Revenue (Billion US$), 2011-2014
  • Figure 6-3: Afinitor - Global Revenue (Billion US$), 2011-2014
  • Figure 6-4: Nexavar - Global Revenue (Billion US$), 2011-2014
  • Figure 6-5: Inlyta - Global Revenue (Billion US$), 2012-2014
  • Figure 6-6: Avastin - Global Revenue (Billion US$), 2011-2014
  • Figure 6-7: Proleukin - Global Revenue (Billion US$), 2012-2014
  • Figure 6-8: Torisel - Global Revenue (Billion US$), 2012 & 2013
  • Figure 7-1: Global - Renal Carcinoma Drugs Market by Geographies (%), 2015
  • Figure 7-2: North America - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
  • Figure 7-3: Europe - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
  • Figure 7-4: Asia-Pacific - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
  • Figure 11-1: Global - Share of Major Players in Renal Cell Carcinoma Drugs Market (%), 2015
  • Figure 12-1: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-2: Roche - Breakup of Pharmaceutical Division Revenue by Geographies (%), 2015
  • Figure 12-3: Novartis - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-4: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-5: Bayer AG - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-7: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-8: AstraZeneca - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-9: Eli Lilly and Company - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-10: Amgen Inc. - Breakup of Revenue by Geographies (%), 2014

List of Tables:

  • Table 8-1: Renal Cell Carcinoma Drugs Pipeline
  • Table 10-1: Mergers & Acquisitions in Renal Cell Carcinoma Drugs Market, 2013-2016
  • Table 11-1: Global - Major Renal Cell Carcinoma Drugs
  • Table 12-1: Pfizer Inc - Revenues by Business Segment (Billion US$), 2012, 2013 & 2014
  • Table 12-2: Pfizer Inc - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-3: Pfizer Inc - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-4: Roche - Revenue by Business Segments (Billion US$), 2013, 2014 & 2015
  • Table 12-5: Roche - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-6: Roche - Renal Cell Carcinoma Drug in Pipeline
  • Table 12-7: Novartis - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-8: Novartis - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-9: Novartis - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-10: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-11: GlaxoSmithKline - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-12: GlaxoSmithKline - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-13: Bayer AG - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-14: Bayer AG - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-15: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-16: Bristol Myers Squibb - Commercialized Renal Cell Carcinoma Drugs
  • Table 12-17: Bristol Myers Squibb - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-18: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-19: Merck & Co., Inc. - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-20: AstraZeneca - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-21: AstraZeneca - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-22: Eli Lilly & Co. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-23: Eli Lilly & Co. - Renal Cell Carcinoma Drugs Pipeline
  • Table 12-24: Amgen Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
  • Table 12-25: Amgen Inc. - Renal Cell Carcinoma Drugs Pipeline
Back to Top